Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

Single-cell gene sequencing has changed the way scientists understand life at the smallest level. It lets researchers study ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...